** Drug developer Eton Pharmaceuticals' ETON.O shares fall 2.2% to $13.39
** Company posts fourth-quarter net loss of 2 cents per share vs analysts' estimate of break even per share, according to data compiled by LSEG
** Company reports product revenue of $11.65 million vs est $10.53 million
** As of last close, Eton Pharma's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.